跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
ORENCIA abatacept (rch) 125 mg single dose syringe subcutaneous injection flange extender - TGA Drug Approval Details
Approvals
/
TGA
/
ORENCIA abatacept (rch) 125 mg single dose syringe subcutaneous injection flange extender
Approved
STANDARD
ORENCIA abatacept (rch) 125 mg single dose syringe subcutaneous injection flange extender
Bristol-Myers Squibb Australia Pty Ltd
🇦🇺 Therapeutic Goods Administration
Approval Date
Dec 9, 2025
Approval ID
e01f0826f05c4242
Company
Bristol-Myers Squibb Australia Pty Ltd
Type
Standard
Approval Details
Approval Id
e01f0826f05c4242
Product Name
ORENCIA abatacept (rch) 125 mg single dose syringe subcutaneous injection flange extender
Artg Id
177176
Artg Name
ORENCIA abatacept (rch) 125 mg single dose syringe subcutaneous injection flange extender
Sponsor
Bristol-Myers Squibb Australia Pty Ltd
Company Detail Path
/organization/bristol-myers-squibb-australia-pty-ltd
Artg Date
2012-01-04
Registration Type
Medicine
Therapeutic Good Type
Medicine
Licence Status
A
Licence Category
RE
Product Information
http://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent=&id=CP-2010-PI-03513-3
Approved
Quick Info
Agency
TGA
Country
🇦🇺
Approval Date
Dec 9, 2025
Approval ID
e01f0826f05c4242
Type
Standard
Back to TGA Approvals